February 2020 Issue of The Medicine Maker

We announce a new Special Series of articles devoted to advanced medicine.

Gene therapies (including CAR T) could add $45 billion to US healthcare costs over the next five years, a CVS health report finds.

The world’s largest cell and gene CDMO, an exciting new TCR, and the global CAR T picture… We examine what’s going on in advanced medicine.

Researchers seek a way to inactivate CAR-T cells in case of adverse effects.

Engineers from Rutgers used 4D printing to create tiny needles with backward-facing barbs. Could these replace hypodermic needles?

UC Davis joins Orgenesis’ point-of-care network to develop and commercialize cell and gene therapies in house.

What challenges do manufacturers face in developing ADCs?

Why are compounds still failing at the final hurdle?

Only when greater transparency is established in supply chains can the industry begin to iron out problems with drug shortages.

John Rossi, Director of Translational Sciences at Kite Pharma, talks about bright future of CAR T cell therapy.

Here we explore the challenges involved in ensuring CAR T cell therapies are delivered to patients safely and as quickly as possible.

Dick Sundh, Head of Europe at Kite, explains what it takes to commercialize CAR T cell therapy.

Aseptic filling is the final manufacturing step but it shouldn’t be an afterthought.

What needs to change to improve our odds in the fight against AMR?

A cell-free biologic could act as platform therapeutic for a variety of serious diseases.

Sitting down with… Matthew Todd, Chair of Drug Discovery at UCL and founder of the Open Source Pharma movement.